ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Nestlé to acquire peanut allergy firm Aimmune in $2.6 billion deal

by Ryan Cross
September 3, 2020 | APPEARED IN VOLUME 98, ISSUE 34

 

Nestlé plans to acquire Aimmune Therapeutics, which recently won US Food and Drug Administration approval of Palforzia, the first treatment designed to reduce allergic reactions to peanuts. Nestlé has invested about $470 million in Aimmune since 2016. The Swiss firm will now buy the rest of Aimmune in a deal valuing it at $2.6 billion. Aimmune previously predicted that peak annual sales of Palforzia could top $1 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment